CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.3B, above the global median of $1.18B
- PositionCurrent ratio is 0.65×, lower than 95% of its Biotechnology peers (median 5.28×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.74BCNY1.30B · vs all stocks (USD)
Revenue (TTM)
1.01BCNY151.04M · vs all stocks (USD)
Profit Margin
-45.36%vs Biotechnology peers
Beta
0.3810xvs all stocks
52-Week Change
-28.55%vs all stocks
Market Capitalization
8.74BCNY1.30B · vs all stocks (USD)
Enterprise Value
8.52BCNY1.27B · vs all stocks (USD)
Forward P/E
-31.03xvs Biotechnology peers
Price to Sales (TTM)
8.63xvs Biotechnology peers
Price to Book (MRQ)
70.57xvs Biotechnology peers
Enterprise to Revenue
8.42xvs Biotechnology peers
Enterprise to EBITDA
-22.42xvs Biotechnology peers
Gross Margin
79.70%vs Biotechnology peers
Profit Margin
-45.36%vs Biotechnology peers
Operating Margin
-35.90%vs Biotechnology peers
Return on Assets (TTM)
-12.94%vs Biotechnology peers
Return on Equity (TTM)
-129.83%vs Biotechnology peers
Revenue (TTM)
1.01BCNY151.04M · vs all stocks (USD)
Revenue per Share (TTM)
2.45CNYUpdated Sep 22, 2026Quarterly Revenue Growth
13.40%vs Biotechnology peers
Gross Profit (TTM)
810.59MCNY121.00M · vs all stocks (USD)
EBITDA (TTM)
-380.00MCNY-56.72M · vs all stocks (USD)
Net Income (TTM)
-458.98MCNY-68.51M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
29.24%vs Biotechnology peers
Operating Cash Flow (TTM)
63.73MCNY9.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-243.60MCNY-36.36M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
935.22MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
197.22MCNYFY2025 · Dec 31, 2025Gross Profit
738.00MCNYFY2025 · Dec 31, 2025Operating Income
-346.27MCNY-51.69M · vs all stocks (USD)
Pre-tax Income
-331.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
292.39KCNYFY2025 · Dec 31, 2025Net Income
-331.94MCNYFY2025 · Dec 31, 2025EBIT
-311.58MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-205.98MCNYFY2025 · Dec 31, 2025Research & Development
800.15MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
273.32MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.85MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
20.07MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8000CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
414.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
414.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-331.94MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-536.13MCNYFY2025 · Dec 31, 2025Free Cash Flow
-657.69MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
218.61MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-331.94MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-166.03MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-59.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-121.56MCNYFY2025 · Dec 31, 2025Purchase of Investments
-880.00MCNYFY2025 · Dec 31, 2025Sale of Investments
971.75MCNYFY2025 · Dec 31, 2025Other Investing Activity
21.11MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.69MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
360.27MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-298.53MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.39MCNYFY2025 · Dec 31, 2025Other Financing Charges
-58.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
41.29MCNYFY2025 · Dec 31, 2025Shares Outstanding
414.08MSharesUpdated Sep 22, 2026Float Shares
107.34MSharesUpdated Sep 22, 2026% Held by Insiders
68.86%vs all stocks
% Held by Institutions
6.34%vs all stocks
Total Cash (MRQ)
395.52MCNY59.04M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9550CNYUpdated Sep 22, 2026Total Debt (MRQ)
898.00MCNY134.05M · vs all stocks (USD)
Total Debt to Equity (MRQ)
7.25xvs Biotechnology peers
Current Ratio (MRQ)
0.6500xvs Biotechnology peers
Book Value per Share (MRQ)
0.2990CNYUpdated Sep 22, 2026Total Assets
2.29BCNY341.43M · vs all stocks (USD)
Total Current Assets
958.56MCNYFY2025 · Dec 31, 2025Total Liabilities
1.91BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.33BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
543.94MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.37BCNYFY2025 · Dec 31, 2025Cash
218.61MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
218.61MCNYFY2025 · Dec 31, 2025Accounts Receivable
164.70MCNYFY2025 · Dec 31, 2025Inventory
312.42MCNYFY2025 · Dec 31, 2025Accounts Payable
198.69MCNYFY2025 · Dec 31, 2025Short-term Debt
311.83MCNYFY2025 · Dec 31, 2025Other Current Liabilities
703.48KCNYFY2025 · Dec 31, 2025Long-term Debt
374.21MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
144.81MCNYFY2025 · Dec 31, 2025Common Stock (Book)
414.08MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.09BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
376.03MCNY56.13M · vs all stocks (USD)
52-Week Low
15.57CNYUpdated Sep 22, 202652-Week High
30.34CNYUpdated Sep 22, 202652-Week Change
-28.55%vs all stocks
Beta
0.3810xvs all stocks
50-Day MA
18.34CNYUpdated Sep 22, 2026200-Day MA
20.79CNYUpdated Sep 22, 2026Avg 10-Day Volume
3.66MSharesUpdated Sep 22, 2026Avg 30-Day Volume
4.40MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-1.11CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.65×, lower than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 0.65Industry median: 5.28Industry P5: 0.98Peers compared: 193
Debt-to-equity is 7.25×, higher than 95% of its Biotechnology peers (median 0.12×)Significant
Debt-to-equity: 7.25Industry median: 0.12Industry P95: 2.33Peers compared: 193
Price-to-book is 70.57×, higher than 95% of its Biotechnology peers (median 4.62×)Significant
Price-to-book: 70.57Industry median: 4.62Industry P95: 31.44Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.80Profit Margin: -0.45
Financial Health
Altman Z-Score 0.59: distress zoneCritical
Altman Z-Score: 0.59
Low earnings qualitySignificant
Earnings Quality Score: -0.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.3B, above the global median of $1.18BNotable
Market cap (USD): 1,304,185,125.76Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Greenland Holdings Corporation Limited
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Guangzhou Jinyi Media Corp.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Shanghai Dobe Cultural & Creative Co., Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone